Life Science Alliance: Closing Research and Innovation Divide in the EU


Acronym Alliance4Life
Funding scheme H2020-SC-1-HCO-08-2017
Grant agreement ID 779303
Implementation period 01.01.2018. – 31.12.2019.
Project coordinator The Central European Institute of Technology (CEITEC) at Masaryk University,  Czech Republic
Project partners The International Clinical Research Center of St. Anne’s University Hospital in Brno, Czech Republic
Biomedical Research Center Slovak Academy of Sciences, Slovakia
The Medical University of Lodz, Poland
University of Zagreb School of Medicine, Croatia
University of Tartu, Estonia
Vilnius University, Lithuania
Latvian Institute of Organic Synthesis, Latvia
University of Ljubljana, Slovenia
Semmelweis University, Hungary


Leader of Latvian team Director of LIOS, Dr. Osvalds Pugovičs
Total Costs 944 652,50 EUR
EU contribution 944 652,50  EUR
Costs for  Latvian partner 131 250,00  EUR


The aim of the project is to establish a European Alliance of ten leading life science research institutions from nine less performing EU-13 countries that are committed to work jointly towards closing the EU divide in health R&I. Alliance4Life consortium will concentrate efforts on

  • mutual learning and sharing practical experience,
  • receiving motivating feedback from high performing research institutions.

Alliance4Life will establish Focus Groups, open platforms for idea generation and exchange of knowledge, working within eight domains of expertise: science evaluation, human resources and recruitment, research funding, core facilities and big data, technology transfer, bio-ethics, science communication, and mobility. In all the domains of expertise, the formation of Alliance4Life enables experience-driven approach focused on best practice cases realized by its members, avoiding actions that failed in the past and promoting those that demonstrated high impact at reasonable cost. The learning process will contribute to institutional reforms in research management and support increased participation in international consortia. The Alliance will develop progressive strategies including suggestions for exploitation of the potential provided by synergies between ESIF and H2020, which will be coordinated with the health R&I managing authorities of the particular less performing countries. The local stakeholders will be motivated to take up proposed strategies through series of national roundtables on institutional and research policy reforms. Spill-over effects will be further fueled by development of training modules and large-scale dissemination of project results.

Alliance4Life Newsletters

Newsletter June 2018
Newsletter January 2019
Newsletter September 2019
Newsletter December 2019